NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has reported progress in its Phase IIA clinical trial evaluating NV-387 Oral Gummies for the treatment of Ebola Bundibugyo virus infection in the Democratic Republic of Congo. The exploratory trial, designed to enroll up to 20 patients with varying disease severity, is assessing the safety and tolerability of treatment regimens ranging from six to 12 days. Although the study is not designed to establish statistically significant efficacy, the company said it may identify preliminary signs of antiviral activity. This development is significant because Ebola remains a highly lethal disease with limited treatment options, and an oral formulation could simplify administration in outbreak settings.
NV-387 is a broad-spectrum antiviral candidate designed to reduce viral load by targeting host-cell features used by viruses during infection. Unlike many antivirals that target the virus itself, this approach may be effective against a wide range of viruses and could reduce the likelihood of resistance. Following completion of the trial and evaluation of the results, NanoViricides plans to advance an appropriate dosing regimen into an expanded, randomized, controlled Phase IIB study, provided the findings support further development. If successful, this could mark a major step forward in the fight against Ebola and other viral diseases.
The company’s pipeline includes NV-387 for respiratory viral infections such as RSV, COVID, and influenza, as well as MPOX/Smallpox and measles. Another advanced candidate, NV-HHV-1, is being developed for the treatment of Shingles. NanoViricides holds a worldwide exclusive perpetual license to the TheraCour nanomedicine technology for several human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza, Dengue, Japanese Encephalitis, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The company is also developing drugs against oral and genital Herpes, viral diseases of the eye, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. For investors, the progress of NV-387 could represent a significant catalyst, as successful clinical trials may lead to regulatory approvals and commercial partnerships. The latest news and updates relating to NNVC are available in the company’s newsroom at https://nnw.fm/NNVC.
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; article and editorial syndication to 5,000+ outlets; enhanced press release enhancement to ensure maximum impact; social media distribution via IBN to millions of social media followers; and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge. Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer.
